Joan Walker to Infusions, Parenteral
This is a "connection" page, showing publications Joan Walker has written about Infusions, Parenteral.
Connection Strength
1.369
-
Randomized Trial of Intravenous Versus Intraperitoneal Chemotherapy Plus Bevacizumab in Advanced Ovarian Carcinoma: An NRG Oncology/Gynecologic Oncology Group Study. J Clin Oncol. 2019 06 01; 37(16):1380-1390.
Score: 0.164
-
Does time interval between surgery and intraperitoneal chemotherapy administration in advanced ovarian cancer carry a prognostic impact? An NRG Oncology/Gynecologic Oncology Group study ancillary study. Gynecol Oncol. 2016 Dec; 143(3):484-489.
Score: 0.137
-
Intraperitoneal chemotherapy for ovarian cancer. Gynecol Oncol. 2016 07; 142(1):1-2.
Score: 0.135
-
Intraperitoneal chemotherapy requires expertise and should be the standard of care for optimally surgically resected epithelial ovarian cancer patients. Ann Oncol. 2013 Dec; 24 Suppl 10:x41-45.
Score: 0.113
-
Prognostic factors for stage III epithelial ovarian cancer treated with intraperitoneal chemotherapy: a Gynecologic Oncology Group study. Gynecol Oncol. 2013 Jul; 130(1):12-8.
Score: 0.108
-
A phase I study with an expanded cohort to assess the feasibility of intravenous paclitaxel, intraperitoneal carboplatin and intraperitoneal paclitaxel in patients with untreated ovarian, fallopian tube or primary peritoneal carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol. 2012 Apr; 125(1):54-8.
Score: 0.098
-
Phase II trial of intraperitoneal cisplatin combined with intravenous paclitaxel in patients with ovarian, primary peritoneal and fallopian tube cancer. Gynecol Oncol. 2011 Sep; 122(3):527-31.
Score: 0.095
-
Intraperitoneal chemotherapy for ovarian cancer: 2009 goals. Gynecol Oncol. 2009 Mar; 112(3):439-40.
Score: 0.081
-
Intraperitoneal chemotherapy for patients with advanced epithelial ovarian cancer: a review of complications and completion rates. Gynecol Oncol. 2008 Feb; 108(2):342-7.
Score: 0.074
-
Results of the 2006 Innsbruck International Consensus Conference on intraperitoneal chemotherapy in patients with ovarian cancer. Cancer. 2007 Feb 15; 109(4):645-9.
Score: 0.070
-
Intraperitoneal chemotherapy of ovarian cancer: a review, with a focus on practical aspects of treatment. J Clin Oncol. 2006 Feb 20; 24(6):988-94.
Score: 0.066
-
Intraperitoneal catheter outcomes in a phase III trial of intravenous versus intraperitoneal chemotherapy in optimal stage III ovarian and primary peritoneal cancer: a Gynecologic Oncology Group Study. Gynecol Oncol. 2006 Jan; 100(1):27-32.
Score: 0.065
-
A phase I pharmacokinetic study of intraperitoneal bortezomib and carboplatin in patients with persistent or recurrent ovarian cancer: An NRG Oncology/Gynecologic Oncology Group study. Gynecol Oncol. 2017 05; 145(2):236-242.
Score: 0.035
-
Update on Intraperitoneal Chemotherapy for the Treatment of Epithelial Ovarian Cancer. Am Soc Clin Oncol Educ Book. 2016; 35:143-51.
Score: 0.033
-
A phase I study of IV doxorubicin plus intraperitoneal (IP) paclitaxel and IV or IP cisplatin in endometrial cancer patients at high risk for peritoneal failure (GOG 9920): an NRG Oncology/Gynecologic Oncology Group study. Gynecol Oncol. 2015 Jul; 138(1):36-40.
Score: 0.031
-
Catumaxomab for the treatment of malignant ascites in patients with chemotherapy-refractory ovarian cancer: a phase II study. Int J Gynecol Cancer. 2014 Nov; 24(9):1583-9.
Score: 0.030
-
Health-related quality of life during and after intraperitoneal versus intravenous chemotherapy for optimally debulked ovarian cancer: a Gynecologic Oncology Group Study. J Clin Oncol. 2007 Feb 01; 25(4):437-43.
Score: 0.018
-
Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med. 2006 Jan 05; 354(1):34-43.
Score: 0.016